MARKET

TNXP

TNXP

Tonix
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.650
-0.560
-25.34%
Closed 16:00 11/15 EST
OPEN
1.500
PREV CLOSE
2.210
HIGH
1.935
LOW
1.480
VOLUME
808.40K
TURNOVER
--
52 WEEK HIGH
96.00
52 WEEK LOW
1.480
MARKET CAP
2.60M
P/E (TTM)
-0.0012
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TNXP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TNXP News

  • Microcaps mostly among midday movers
  • Seeking Alpha - Article.1d ago
  • Tonix Pharma Prices ~547.4K Class A Unit, Warrants Offering At $1.94/Unit, Gross Proceeds $9M
  • Benzinga.1d ago
  • Tonix Pharmaceuticals Prices $9.0 Million Public Offering
  • GlobeNewswire.1d ago
  • The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
  • Benzinga.1d ago

More

Industry

Biotechnology & Medical Research
+1.25%
Pharmaceuticals & Medical Research
+1.34%

Hot Stocks

Name
Price
%Change

About TNXP

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).
More

Webull offers Tonix Pharmaceuticals Holding Corp (TNXP) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.